Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

127

Participants

Timeline

Start Date

April 7, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

November 30, 2021

Conditions

Early Stage Breast Cancer

Interventions

DRUG

Paclitaxel

DRUG

Neulasta

Trial Locations (4)

Dana-Farber Cancer Institute, Boston

Dana-Farber at Milford Regional Cancer Center, Milford

Dana-Farber Cancer Institute at South Shore, Weymouth

Dana-Farber/New Hampshire Oncology-Hematology, Londonderry

All Listed Sponsors

lead

Dana-Farber Cancer Institute

OTHER

NCT02698891 - Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | Biotech Hunter | Biotech Hunter